MyAverix Finance MyAverix Finance

LSE

Ultragenyx Pharmaceutical Inc. (0LIF)

Ultragenyx Pharmaceutical Inc. (0LIF) is listed on LSE. As of 2026-05-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 0LIF

P/E ratio
18.00

Ultragenyx Pharmaceutical Inc. (0LIF) — FAQ

What is 0LIF's P/E ratio?

The price-to-earnings (P/E) ratio for Ultragenyx Pharmaceutical Inc. (0LIF) is 18.00 (data as of 2026-05-23).

Does Ultragenyx Pharmaceutical Inc. pay a dividend?

Dividend yield is not available in the current snapshot for Ultragenyx Pharmaceutical Inc. (0LIF). Check the MyAverix Finance app for the latest dividend data.

What exchange is 0LIF listed on?

0LIF is listed on LSE.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play